Similar articles

• The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule.

  Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Yamamoto N, Fujii N. Weeks BS, et al. Biochem Biophys Res Commun. 1995 Oct 13;215(2):626-31. doi: 10.1006/bbrc.1995.2510. Biochem Biophys Res Commun. 1995. PMID: 7488001
• Interaction of an anti-HIV peptide, T22, with gp120 and CD4.

  Tamamura H, Otaka A, Murakami T, Ishihara T, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N. Tamamura H, et al. Biochem Biophys Res Commun. 1996 Feb 15;219(2):555-9. doi: 10.1006/bbrc.1996.0272. Biochem Biophys Res Commun. 1996. PMID: 8605026
• Structure-activity relationships of an anti-HIV peptide, T22.

  Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N, et al. Tamamura H, et al. Biochem Biophys Res Commun. 1994 Dec 30;205(3):1729-35. doi: 10.1006/bbrc.1994.2868. Biochem Biophys Res Commun. 1994. PMID: 7811258
• [Antiviral compounds: current approaches for development].

  Suzutani T, Azuma M. Suzutani T, et al. Nihon Rinsho. 1993 Jul;51(7):1907-14. Nihon Rinsho. 1993. PMID: 8366615 Review. Japanese.
• Basic approaches to anti-retroviral treatment.

  De Clercq E. De Clercq E. J Acquir Immune Defic Syndr (1988). 1991;4(3):207-18. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1704059 Review. No abstract available.